Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA modulatorbenzodiazepines, alcohol, barbiturates +1 morebenzodiazepines, alcohol, barbiturates, GABA-A positive allosteric modulators show less
Nifoxipam
Nifoxipam is a synthetic depressant of the benzodiazepine class. It is the primary active metabolite of flunitrazepam (Rohypnol). It amplifies the brain's main inhibitory system — GABA — producing the heavy, prolonged sedation characteristic of benzodiazepines.[1]
Nifoxipam (5-(2-fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one) is a synthetic depressant of the benzodiazepine class. It is the primary active metabolite of flunitrazepam, distinguished by unusually low potency and exceptionally long duration. Nifoxipam is a positive allosteric modulator of GABA-A receptors, producing its effects by amplifying the brain's primary inhibitory signaling system.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA modulatorbenzodiazepines, alcohol, barbiturates +1 morebenzodiazepines, alcohol, barbiturates, GABA-A positive allosteric modulators show less
Nifoxipam emerged from metabolic studies of flunitrazepam in the 1960s and was never developed as an independent drug.[2] It appeared on the designer drug market in April 2014, exploiting the gap between flunitrazepam's controlled status and its unscheduled metabolite.[3] It is now explicitly scheduled in the UK and Denmark, covered by blanket psychoactive substance laws in other countries, and still unscheduled in many others.
Subjective effects include anxiety suppression, sedation, muscle relaxation, amnesia, and disinhibition. The experience is a flat, prolonged numbness — notably lacking the euphoria characteristic of more potent designer benzodiazepines.[4] Compulsive redosing, cognitive impairment, and memory blackouts are common unwanted effects.
Nifoxipam carries high physical and psychological dependence liability, and abrupt cessation can trigger life-threatening withdrawal.[5] Combining it with opioids or alcohol dramatically amplifies the risk of breathing failure; its duration of up to 75 hours makes dose accumulation a distinct hazard.[6][3] No controlled human studies exist — what is known comes from forensic cases and analytical chemistry.[3]
History[edit]
Discovery
Nifoxipam was not designed as a drug in its own right. It was identified during metabolic research on flunitrazepam (Rohypnol), which the body breaks down into nifoxipam — a compound that retains activity at GABA receptors.[3][7] It was never developed as an independent pharmaceutical.[2]
Designer drug emergence
The first confirmed seizure occurred in April 2014 in Visby, Sweden — brown tablets exploiting the gap between flunitrazepam's controlled status and its unscheduled metabolite.[3][2] Over the following year, seizures spread across Finland, Norway, Slovenia, Denmark, and France,[3] and the compound later appeared in North American poison control data.[8]
Regulatory response
Denmark scheduled nifoxipam in February 2016. The UK's Psychoactive Substances Act 2016 provided blanket coverage from May 2016,[2] and the UK subsequently added it explicitly as a Class C, Schedule 1 substance in May 2017.[9]
The name nifoxipam follows standard benzodiazepine naming conventions. Alternative designations include 3-hydroxydesmethylflunitrazepam, DP-370, and DP370.[3] It exemplifies a recurring strategy in the designer drug market: using a well-characterized metabolite of a controlled drug to deliver pharmacologically active material while sidestepping regulations targeting the parent compound.
Chemistry[edit]
Structural class
Nifoxipam belongs to the 1,4-benzodiazepine family, specifically the nitrobenzodiazepine subclass — the same chemical lineage as flunitrazepam, clonazepam, and nitrazepam. It is the N-desmethyl-3-hydroxy derivative of flunitrazepam, differing by the loss of one methyl group and the addition of a hydroxyl group.[3] That 3-hydroxyl group increases water solubility, which may partly explain nifoxipam's lower potency by reducing how much of it enters the brain.[4]
Molecular identity
Its molecular formula is C₁₅H₁₀FN₃O₄ (molecular weight 315.26 g/mol). The combination of a carbonyl at position 2 and a hydroxyl at position 3 is the same pharmacophore found in stand-alone pharmaceutical benzodiazepines like oxazepam and lorazepam.[3] Physical property data derive from chemical supplier documentation rather than peer-reviewed literature.[10]
Pharmacology[edit]
Mechanism of action
Nifoxipam is a positive allosteric modulator of GABA-A receptors — it binds at the classical benzodiazepine site and makes the brain's own GABA more effective, increasing how often chloride channels open without triggering them directly.[1][3] The result is amplified inhibitory signaling throughout the central nervous system, producing a dose-dependent continuum from anxiety relief through sedation to respiratory depression.[1]
Pharmacokinetics
No controlled human pharmacokinetic studies exist for nifoxipam. After oral administration, effects begin 45–120 minutes after ingestion[3] and may last anywhere from 10 to 75 hours — a sevenfold range reflecting dose differences, individual metabolism, and the compound's expected long half-life.[3]
Metabolism
Nifoxipam is itself a metabolite of flunitrazepam. The body converts it further to 7-acetaminonifoxipam — the primary compound detectable in urine and the standard forensic testing target.[11] A second breakdown pathway (glucuronidation) requires enzyme complexes rather than a single enzyme — an unusual feature that distinguishes nifoxipam from most other designer benzodiazepines.[12] Standard immunoassay screens will flag nifoxipam but cannot identify it specifically.[13]
Neuroscience[edit]
Where it acts
No brain imaging or electrophysiology studies exist for nifoxipam. Based on benzodiazepine class pharmacology, anxiety relief comes from dampening fear circuits in the amygdala, while sedation and amnesia arise from cortical and hippocampal inhibition.[1] High doses progressively suppress cortical function, producing cognitive impairment, blackouts, and loss of consciousness.[6]
Why it matters
Benzodiazepines also suppress inhibitory neurons in the brain's reward circuitry, releasing dopamine and contributing to reinforcement and abuse liability. Nifoxipam's muted euphoria[4] may reflect weaker engagement with this mesolimbic pathway — consistent with its lower overall potency compared to designer analogs like flubromazolam or clonazolam.
No binding affinity data exist for nifoxipam, so potency estimates rely entirely on user reports.[3] Its unusual metabolic enzyme profile[12] suggests drug interaction risks may differ from standard benzodiazepine assumptions. The sevenfold range in reported duration (10–75 hours) remains unexplained without controlled pharmacokinetic measurement.
Subjective Effects[edit]
Nifoxipam produces heavy, drawn-out sedation. Anxiety fades, muscles relax, and the mind grows cloudy — not in a pleasant dreamy way, but in a flat, numbing heaviness that can persist for many hours. Euphoria is minimal. The experience is defined by what it removes rather than what it adds.
Compared to flunitrazepam, nifoxipam is substantially weaker but far longer-lasting. Among designer benzodiazepines, it sits closest to pyrazolam and metizolam in potency but outlasts both.[4] The muted euphoria stands in sharp contrast to high-potency analogs like flubromazolam or etizolam.[4]
Identified during metabolic studies of flunitrazepam in the 1960s, nifoxipam was never developed as an independent pharmaceutical.[2] It appeared on the designer drug market in April 2014 when tablets were first seized in Sweden, exploiting the regulatory gap between a controlled parent compound and its unscheduled metabolite.[3] It is now explicitly controlled in several European jurisdictions and covered by blanket psychoactive substance legislation in others.
Subjective effects include anxiety suppression, sedation, muscle relaxation, and amnesia. The experience is one of muted, prolonged sedation — a flat, heavy calm without the pronounced euphoria characteristic of more potent designer benzodiazepines.[4] Disinhibition, compulsive redosing, and cognitive impairment are common unsought effects.
Nifoxipam carries high physical and psychological dependence liability, inferred from its parent compound and the benzodiazepine class as a whole.[5] The primary acute danger is respiratory depression in combination with other depressants,[6] compounded by a duration spanning up to 75 hours that creates significant dose-accumulation risk.[3] No controlled pharmacological, toxicological, or clinical studies have been published — the entire evidence base rests on forensic case reports and analytical chemistry.[3]
History[edit]
Discovery
Nifoxipam was not designed as a drug in its own right. It emerged from metabolic studies of flunitrazepam (Rohypnol), a potent nitrobenzodiazepine first synthesized in 1963 by Leo Sternbach at Hoffmann-La Roche.[7] Flunitrazepam undergoes sequential breakdown in the body to yield nifoxipam as an active metabolite that retains activity at GABA-A receptors.[3] A 1985 European patent (EP 0158267) implicitly covers its synthesis, but nifoxipam was never developed as an independent pharmaceutical.[2]
Designer drug emergence
Nifoxipam appeared on the novel psychoactive substance market in 2014, part of a wave of designer benzodiazepines that marketed metabolites and structural analogs of controlled drugs to exploit regulatory gaps. The first confirmed seizure occurred in April 2014 in Visby, Sweden, where 20 brown tablets were identified through laboratory analysis.[3][2] Over the following year, seizures spread across Finland, Norway, Slovenia, Denmark, and France,[3] and the compound was subsequently confirmed in the North American market through US poison control data.[8]
Regulatory response
Scheduling followed detection with the typical lag for novel psychoactive substances. Denmark controlled nifoxipam in February 2016, and the UK Psychoactive Substances Act 2016 provided blanket coverage from May 2016.[2] The UK subsequently added nifoxipam explicitly as a Class C, Schedule 1 substance under the Misuse of Drugs Act in May 2017.[9]
The name nifoxipam follows standard benzodiazepine nomenclature conventions. Alternative designations include 3-hydroxydesmethylflunitrazepam, DP-370, and DP370.[3] The compound exemplifies a recurring strategy in the designer drug market: repurposing a well-characterized metabolite of an internationally controlled substance to deliver pharmacologically active material while sidestepping regulations targeting the parent compound.
Chemistry[edit]
Structural class
Nifoxipam belongs to the 1,4-benzodiazepine chemical family, specifically the nitrobenzodiazepine subclass defined by a nitro group at the 7-position of the fused aromatic ring. This subclass includes flunitrazepam, clonazepam, and nitrazepam. Structurally, nifoxipam is the N-desmethyl-3-hydroxy derivative of flunitrazepam — it differs from its parent by the loss of a methyl group at position 1 and the addition of a hydroxyl group at position 3.[3]
The 2-fluorophenyl group at position 5 is shared with flunitrazepam and distinguishes this lineage from chlorinated nitrobenzodiazepines like clonazepam. The 3-hydroxyl group increases water solubility relative to flunitrazepam, a modification that may partially explain nifoxipam's lower observed potency by reducing penetration into the brain.[4]
Molecular identity
| Molecular formula | C₁₅H₁₀FN₃O₄ |
| Molecular weight | 315.26 g/mol |
The core structure consists of a seven-membered diazepine ring fused to a nitro-substituted benzene ring and bearing a 2-fluorophenyl group. The carbonyl at position 2 and hydroxyl at position 3 define a pharmacophore shared with several benzodiazepine metabolites that became independent pharmaceuticals, including oxazepam and lorazepam.[3]
Stereochemistry
The 3-hydroxyl group creates a chirality center at C-3. No published data address the stereoselective activity of nifoxipam's enantiomers, and commercially available material is presumed to be racemic mixture. In structurally analogous 3-hydroxybenzodiazepines such as oxazepam, one enantiomer is the more pharmacologically active form,citation needed but this has not been confirmed for nifoxipam.
Physical properties
| Appearance | White to off-white crystalline solid |
| Melting point | 194–196 °C |
| Solubility | Greater aqueous solubility than flunitrazepam; soluble in organic solvents |
| Stability | Powder stable approximately 2 years under appropriate storage |
Physical property data derive from chemical supplier documentation rather than peer-reviewed literature.[10] A logP value of 10.45 has been reported in some databases,[10][2] but this value is almost certainly erroneous — 3-hydroxybenzodiazepines are expected to have logP values in the 1.5–3.0 range, and a value of 10.45 is physically inconsistent with the molecular structure.
Pharmacology[edit]
Mechanism of action
Nifoxipam is a positive allosteric modulator of GABA-A receptors, binding at the classical benzodiazepine site between the α and γ₂ subunits.[1][3] It does not activate the chloride channel directly; instead, it increases the frequency of channel opening when the brain's own GABA is present, amplifying inhibitory signaling throughout the central nervous system.[1] The pharmacological result is a dose-dependent continuum from anxiolysis through sedation to respiratory depression at high exposure.
As a nitrobenzodiazepine, nifoxipam shares its structural class with flunitrazepam, which demonstrates greater potency and higher receptor affinity than most standard benzodiazepines.[1] Nifoxipam retains activity at the same receptor site,[3] but no binding affinity measurements have been published for it at any receptor target.[3] Its potency ranking relies entirely on user reports and computational prediction.
Pharmacokinetics
No controlled human pharmacokinetic studies exist for nifoxipam. Onset of effects after oral administration is 45–120 minutes.[3] The wide range likely reflects individual differences in stomach conditions, food intake, and liver metabolism.
Total duration of subjective effects spans approximately 10–75 hours.[3] This sevenfold range — derived from user reports synthesized in the Katselou et al. review, not controlled measurement — likely reflects dose variability, metabolic differences, polydrug use, and the compound's expected long half-life.
Metabolism
Nifoxipam is itself an active metabolite of flunitrazepam (the N-desmethyl-3-hydroxy derivative).[3] Its primary metabolic pathway involves reduction of the 7-nitro group to produce 7-aminonifoxipam, followed by acetylation to 7-acetaminonifoxipam — the most abundant urinary metabolite and the recommended target for forensic drug testing.[11]
Glucuronidation of the parent compound produces a significant secondary urinary metabolite.[12] Unusually, this glucuronide conjugation was detected only in pooled liver preparations and not when individual metabolic enzymes were tested separately,[12] suggesting the process requires enzyme complexes rather than a single enzyme. This distinguishes nifoxipam from most other designer benzodiazepines, which are processed by a single identified enzyme.[12]
Standard immunoassay benzodiazepine screens show high cross-reactivity with nifoxipam,[13] though confirmatory laboratory analysis is required for definitive identification.
Neuroscience[edit]
Where it acts
No direct brain imaging or electrophysiology studies have been performed with nifoxipam. From benzodiazepine class pharmacology, the compound enhances inhibitory signaling across widespread brain circuits. Anxiety suppression arises primarily from dampening fear-processing circuits in the amygdala. Sedation and amnesia are mediated through cortical and hippocampal regions, while muscle relaxation involves spinal cord and brainstem circuits.[1] At high doses, progressive cortical inhibition produces cognitive impairment, memory blackouts, and loss of consciousness.[6]
Why it matters
Benzodiazepines also indirectly affect reward circuitry by suppressing inhibitory neurons in the brain's ventral tegmental area, which releases dopamine and contributes to their reinforcing properties and abuse liability. Nifoxipam's relatively modest euphoria[4] may reflect weaker engagement of this mesolimbic pathway, consistent with its lower overall potency compared to designer analogs like flubromazolam or clonazolam.
Several fundamental questions remain unanswered. No binding affinity data exist, so potency ranking relies entirely on subjective reports — direct receptor binding measurements could resolve the anomalous potency discrepancy identified by El Balkhi et al..[4] The unusual metabolic enzyme profile[12] suggests drug interaction risks may differ from standard benzodiazepine assumptions, but no enzyme-specific studies have been conducted. The sevenfold range in reported duration (10–75 hours) remains unexplained without controlled pharmacokinetic measurement.
Subjective Effects[edit]
Nifoxipam produces a benzodiazepine experience dominated by heavy, drawn-out sedation. At threshold doses, anxiolysis and mild muscle relaxation emerge without pronounced cognitive impairment. As dosage increases, sedation deepens, amnesia sets in, and disinhibition becomes increasingly apparent — the experience flattens into a protracted numbness rather than building toward euphoria. Set and setting have moderate influence: anxious environments may blunt the anxiolytic ceiling, but the pharmacological sedation overrides context more reliably than with psychedelics or stimulants.
Compared to flunitrazepam, nifoxipam is substantially weaker but longer-lasting — a low-ceiling, high-duration outlier within the nitrobenzodiazepine family. Among designer benzodiazepines, it sits closest to pyrazolam and metizolam in potency but outlasts both.[4] The euphoric component is notably muted relative to etizolam or high-potency analogs like flubromazolam and clonazolam.[4]
Effect Grid
Common doses (0.5–1 mg oral) produce clear anxiolysis, moderate sedation, and noticeable muscle relaxation. Cognitive euphoria may emerge — though it is notably less prominent than with etizolam or high-potency designer benzodiazepines. Emotional suppression flattens affective reactivity. Thought deceleration and analysis suppression become apparent.
Amnesia may begin at this tier, particularly toward the upper end. Disinhibition is noticeable — users may behave or communicate in ways inconsistent with their sober baseline. Motor control impairment affects fine coordination. One user report described cumulative 8 mg as producing "benzodiazepine-like sedation and anti-anxiety effects along with slight euphoria" — common doses produce these effects at lower intensity.
Delusions of sobriety are possible: users may significantly underestimate their level of impairment, increasing redosing risk during the long onset window.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Proprioceptive distortion
Dizziness · Bodily heaviness · Body high · Pain suppression · Nystagmus (eye wobbles) · Insomnia · Nausea · Headache
Nystagmus (eye wobbles) · Insomnia · Nausea · Headache
Cognitive impairment · Cognitive fatigue · Motivation suppression · Focus suppression · Information processing suppression · Thought disorganization · Cognitive euphoria · Memory fragmentation · Creativity suppression · Compulsive redosing urge · Confusion · Language suppression · Suggestibility enhancement · Humor enhancement · Amnesia · Delirium
Focus suppression · Information processing suppression · Thought disorganization · Cognitive euphoria · Memory fragmentation · Creativity suppression · Confusion · Language suppression · Suggestibility enhancement · Humor enhancement · Amnesia · Delirium
Anxiety
Communication enhancement · Automaticity · Depersonalization · Derealization
Timeline
Gradual emergence of subtle relaxation and anxiolytic warmth. Effects may be barely perceptible initially, building slowly over 45–120 minutes.
Progressive deepening of sedation and anxiety suppression. Muscle relaxation becomes noticeable; mild motor control impairment may begin.
Full anxiolysis, sedation, and muscle relaxation. Cognitive euphoria possible at moderate doses. Amnesia and disinhibition emerge at common-to-strong doses.
Gradual reduction in peak intensity while sedation and anxiolysis persist. Residual motor control impairment and cognitive fog continue. Duration highly variable (4–24 hours).
Lingering sedation and possible rebound anxiety in regular users. Cognitive processing may remain subtly impaired for hours after subjective effects resolve.
⚠ Do not drive or operate machinery for at least 24 hours after last perceived subjective effects, given the compound's extremely long and variable duration.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · alcohol · barbiturates
Toxicity
No controlled toxicity data exist for nifoxipam in any species. No lethal dose, therapeutic index, or organ toxicity profile has been published, and no death attributed solely to nifoxipam has been reported in the peer-reviewed literature.[3]
Acute toxicity
Respiratory depression is the primary life-threatening risk, occurring at high doses or — far more commonly — when combined with other depressants.[6][1] The dose-response continuum runs from sedation through stupor to coma.
Clinical data from the Swedish STRIDA project (five confirmed cases) showed central nervous system depression as the dominant finding; all cases involved multiple substances.[14] Across US poison control data for designer benzodiazepines (2014–2017), 36% of single-agent exposures required hospital admission, 22% required intensive care, and 3% required a breathing tube.[8]
Chronic toxicity
No chronic toxicity data exist for nifoxipam. Class-level benzodiazepine data suggest cognitive impairment with prolonged use, but no nifoxipam-specific evidence is available.inferred
Drug-facilitated crime risk
Nifoxipam shares its structural origin with flunitrazepam (Rohypnol), which has an established history of use in drug-facilitated sexual assault. Designer benzodiazepines have been identified as emerging agents in this context[16][17]: active at low doses, producing amnesia and disinhibition, dissolving in beverages, and evading standard drug screens unless laboratories specifically test for their metabolites.[3]
Flumazenil reversal
Psychological risks
No controlled data characterize nifoxipam-specific psychological risks. The following are inferred from benzodiazepine class pharmacology:
Delusions of sobriety: At moderate doses, users may significantly underestimate impairment, increasing risk of driving and compulsive redosing.inferred
Amnesia: Memory blackouts prevent accurate recall of events during intoxication and increase vulnerability to exploitation.
Disinhibition: Reduced behavioral inhibition may lead to impulsive actions inconsistent with baseline personality.
Compulsive redosing: The slow onset (45–120 minutes) and long duration create a window in which a second dose is taken before the first reaches peak effect, causing unintended accumulation.
Paradoxical reactions: Benzodiazepines occasionally produce agitation or aggression rather than sedation, particularly in elderly individuals and those with personality disorders.citation needed
Tolerance and dependence
Tolerance to sedation, anxiety relief, and sleep develops within days of continuous use.[3] Full cross-tolerance exists with all benzodiazepines, alcohol, and barbiturates.[5]
Nifoxipam carries high physical and psychological dependence liability — inferred from flunitrazepam and the benzodiazepine class, not from nifoxipam-specific studies.[3]safety citation needed
Drug Interactions
No published interaction data specific to nifoxipam exist. All interactions are inferred from benzodiazepine class pharmacology.
Opioids: Breathing failure is the primary lethal outcome. Combining benzodiazepines with opioids can cause respiratory arrest and death.[6]
Alcohol: Synergistic central nervous system depression. At just 1 mg nifoxipam combined with alcohol, one report documented rapid potentiation.[3]
Barbiturates, gabapentinoids, Z-drugs, and other benzodiazepines: All produce additive depression through overlapping inhibitory mechanisms.
Flumazenil: Reverses nifoxipam-induced sedation (confirmed clinically[14]) but is contraindicated when cyclic antidepressant co-ingestion is suspected.
Liver enzyme inhibitors and inducers: Drugs like ketoconazole or rifampin may alter nifoxipam's blood levels, though this remains a theoretical interaction.inferred
Contraindications
7 knownNo nifoxipam-specific contraindication data exist. The following are derived from benzodiazepine class pharmacology:
Breathing problems: Pre-existing compromised respiratory function increases the risk of fatal respiratory depression.safety citation needed
Concurrent depressant use: Co-administration with opioids, alcohol, barbiturates, or other depressants is the primary mechanism of benzodiazepine-related fatality.
Severe liver disease: Nifoxipam undergoes liver metabolism;[11][12] severe impairment may prolong effects unpredictably.
Pregnancy and breastfeeding: Benzodiazepines cross the placenta and enter breast milk. Neonatal withdrawal and floppy infant syndrome are established class risks.safety citation needed
Myasthenia gravis: GABA enhancement may worsen muscle weakness.inferred
History of paradoxical benzodiazepine reactions: Prior paradoxical agitation with any benzodiazepine contraindicates further use.
Narrow-angle glaucoma: Benzodiazepines may worsen eye pressure.inferred
Harm Reduction[edit]
Forms & Identification
Nifoxipam has circulated primarily as pressed tablets and loose powder. Visual inspection cannot confirm identity or dose — the compound is active at low milligram doses and appearance varies between batches.[3] Standard immunoassay benzodiazepine screens will flag nifoxipam,[13] but laboratory confirmation is needed to distinguish it from other benzodiazepines.
Guidelines
- Test all material with reagent kits and, where possible, laboratory analysis before use. Reagent testing cannot confirm dose but can identify some substitutions.
- Start at the lowest reported active dose and do not redose for at least 4–6 hours. The 45–120 minute onset window[3] means early redosing is the most common path to unintended overdose.
- Use a milligram-precision scale. Volumetric dosing of solutions is preferable to weighing sub-milligram differences in powder.
- Keep all other depressants — especially alcohol and opioids — completely out of the session. Even low doses combined with alcohol have produced rapid potentiation.[3]
- Write down what was taken, how much, and when. Amnesia may prevent recall of this information, and it is critical for medical responders.
- Do not use alone. A sober sitter who knows what was taken can intervene if breathing becomes shallow or the person becomes unresponsive.
Set & Setting
Nifoxipam's extended duration — potentially spanning multiple days — demands planning that shorter-acting benzodiazepines do not. Clear all obligations for at least 24–48 hours following administration. A trusted sober companion is advisable given the compound's propensity for amnesia and delusions of sobriety, which may prevent accurate self-assessment of impairment. Driving and operating machinery are unsafe for the full duration of effects, which may persist long after feeling subjectively sober.
Aftercare & integration. Residual sedation, cognitive impairment, and impaired coordination may persist for 24–72 hours after administration. Avoid driving, important decisions, and situations requiring sharp judgment during this period.
Hydration and light meals support recovery. Sleep disruption is common in the days following use — maintain a regular sleep schedule and avoid caffeine in the evening. If amnesia occurred, seek a trusted account of events from anyone who was present.
Recovery & Support
Benzodiazepine dependence develops with sustained use and produces a withdrawal that can be life-threatening.[5] Anyone who has used nifoxipam or other benzodiazepines regularly should not stop abruptly — medical supervision is essential for safe tapering.
Support resources include the SAMHSA National Helpline (1-800-662-4357, US), local addiction medicine services, and benzodiazepine-specific peer support communities such as BenzoBuddies. A physician experienced in benzodiazepine tapering can design a gradual dose-reduction schedule, often using a long-acting pharmaceutical benzodiazepine as a bridge.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Slow, shallow, or stopped breathing
- Blue or grey lips and fingertips
- Unresponsiveness — cannot be woken by shouting or sternal rub
- Snoring or gurgling sounds in an unconscious person (signs of airway obstruction)
Immediate steps:
- Call emergency services immediately if breathing is slow, stopped, or the person cannot be woken.
- Place the person in the recovery position (on their side, mouth facing downward) to prevent choking on vomit.
- Monitor breathing continuously until help arrives. If breathing stops, begin rescue breathing if trained.
- Do NOT induce vomiting. Do NOT leave the person alone.
What to tell the dispatcher:
- "They took a designer benzodiazepine called nifoxipam."
- State the approximate amount and time of ingestion.
- Report any other substances taken, especially opioids or alcohol.
- Describe current symptoms: breathing rate, responsiveness, skin color.
- Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil reverses benzodiazepine sedation and has been used successfully in nifoxipam cases.[14] Nifoxipam's effects can last far longer than flumazenil's (up to 75 hours vs. 1–2 hours), so re-sedation is likely and repeated dosing may be needed. Flumazenil should only be given by medical professionals.
Legal Status[edit]
Nifoxipam is explicitly scheduled in a growing number of jurisdictions and covered by blanket psychoactive substance legislation in others; it remains unscheduled in many countries.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class C, Schedule 1 (Misuse of Drugs Act 1971) | Added via SI 2017/631 (May 2017); tightest control category — no recognized medical use; also covered by Psychoactive Substances Act 2016[9][2] |
| Denmark | Controlled substance | Controlled from February 18, 2016[3][2] |
| United States | Not federally scheduled | Potentially prosecutable under the Federal Analogue Act as a structural and pharmacological analog of flunitrazepam (Schedule IV); state-level scheduling may applycitation needed |
| Australia | Controlled substance (ODC listing) | Listed by the Australian Office of Drug Control; specific scheduling tier not confirmed from primary sourcescitation needed |
| Canada | Possible Schedule IV coverage | Benzodiazepine analogs may fall under CDSA Schedule IV; specific nifoxipam status requires verificationcitation needed |
| Sweden | Status unconfirmed | STRIDA project documented intoxication cases;[14] specific scheduling legislation not confirmed |
| Finland, Norway, Slovenia, France | Seizures reported 2014–2015 | Nifoxipam tablets seized in all four countries;[3] individual scheduling status not confirmed |
Analog act considerations
In the United States, the Federal Analogue Act treats substances substantially similar to a Schedule I or II drug as Schedule I when intended for human consumption. Nifoxipam is a direct metabolite of flunitrazepam (Schedule IV, not Schedule I/II), placing it in an ambiguous position under the Act's literal text. Structural similarity to other scheduled benzodiazepines may provide alternative bases for prosecution.
Nifoxipam is listed in the UNODC Early Warning Advisory database but is not placed under any UN convention schedule.[18]
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · alcohol · barbiturates
Toxicity
No controlled toxicity data exist for nifoxipam in any species. No lethal dose, therapeutic index, or organ toxicity profile has been published.[3] No death attributed solely to nifoxipam has been reported in the peer-reviewed literature.[3]
Acute toxicity
Respiratory depression is the primary life-threatening risk, occurring at high doses or — far more commonly — in combination with other depressants.[6][1] The dose-response continuum proceeds from sedation through stupor to coma.
Clinical data from the Swedish STRIDA project (five confirmed cases) showed central nervous system depression as the most prominent finding; all cases involved multiple substances.[14] Across US poison control data for designer benzodiazepines (2014–2017), 36% of single-agent exposures required hospital admission, 22% required intensive care, and 3% required a breathing tube.[8]
Chronic toxicity
No chronic toxicity data exist for nifoxipam. Long-term organ effects cannot be characterized from published sources. Class-level benzodiazepine data suggest cognitive impairment with prolonged use, but no nifoxipam-specific evidence is available.inferred
Drug-facilitated crime risk
Nifoxipam shares its structural origin with flunitrazepam (Rohypnol), which has an established history of use in drug-facilitated sexual assault. Designer benzodiazepines have been identified as emerging agents in this context[16][17]: they are active at low doses, produce amnesia and disinhibition, dissolve in beverages, and evade standard drug screens unless laboratories specifically test for their metabolites.[3]
Flumazenil reversal
Psychological risks
No controlled data characterize nifoxipam-specific psychological risks. The following are inferred from benzodiazepine class pharmacology:
Delusions of sobriety: Users at moderate doses may significantly underestimate their impairment, increasing the risk of driving, operating machinery, and compulsive redosing.inferred
Amnesia: Memory blackouts prevent accurate recall of events during intoxication, complicating medical assessment and increasing vulnerability to exploitation.
Disinhibition: Reduced behavioral inhibition may lead to impulsive actions inconsistent with baseline personality.
Compulsive redosing: The slow onset (45–120 minutes) and long duration create a window in which users may redose before the initial dose reaches peak effect, causing unintended dose accumulation.
Paradoxical reactions: Benzodiazepines occasionally produce paradoxical agitation, aggression, or disinhibition, particularly in elderly individuals and those with personality disorders.citation needed
Tolerance and dependence
Tolerance to the sedative, anxiolytic, and sleep-promoting effects develops within a few days of continuous use.[3] Full cross-tolerance exists with all benzodiazepines, alcohol, barbiturates, and other drugs acting at the same receptor site.[5]
Nifoxipam carries high physical and psychological dependence liability — a characterization derived from flunitrazepam and class-level benzodiazepine data, not from nifoxipam-specific studies.[3]safety citation needed
Drug Interactions
No published interaction data specific to nifoxipam exist. All interactions are inferred from benzodiazepine class pharmacology.
Opioids: Additive respiratory depression constitutes the primary lethal combination. Illicitly obtained benzodiazepines combined with opioids can cause respiratory arrest and death.[6]
Alcohol: Synergistic depression of the central nervous system. One user report documented rapid euphoric effects when 1 mg nifoxipam was combined with alcohol,[3] demonstrating meaningful potentiation even at low doses.
Barbiturates, gabapentinoids, Z-drugs, and other benzodiazepines: All produce additive depression through overlapping mechanisms at inhibitory signaling systems.
Flumazenil: Reverses nifoxipam-induced sedation (confirmed clinically[14]) but is contraindicated when cyclic antidepressant co-ingestion is suspected.
Liver enzyme inhibitors and inducers: Drugs that inhibit or accelerate liver metabolism (e.g., ketoconazole, rifampin) may alter nifoxipam's blood levels, though this remains a theoretical interaction.inferred
Contraindications
7 knownNo nifoxipam-specific contraindication data exist. The following are derived from benzodiazepine class pharmacology:
Breathing problems: Pre-existing compromised respiratory function increases the risk of fatal respiratory depression.safety citation needed
Concurrent depressant use: Co-administration with opioids, alcohol, barbiturates, or other depressants is the primary mechanism of benzodiazepine-related fatality.
Severe liver disease: Nifoxipam undergoes liver metabolism;[11][12] severe impairment may prolong effects unpredictably.
Pregnancy and breastfeeding: Benzodiazepines cross the placenta and are excreted in breast milk. Neonatal withdrawal and floppy infant syndrome are established class risks.safety citation needed
Myasthenia gravis: GABA-A enhancement may worsen muscle weakness.inferred
History of paradoxical benzodiazepine reactions: Prior paradoxical agitation or disinhibition with any benzodiazepine contraindicates further use.
Narrow-angle glaucoma: Benzodiazepines may worsen eye pressure.inferred
Harm Reduction[edit]
Forms & Identification
Nifoxipam has circulated primarily as pressed tablets and loose powder through online vendors. Because the compound is active at low milligram doses, visual inspection cannot confirm identity or dose. The tablets seized in Sweden and Finland varied in color and marking,[3] and no standardized appearance exists across batches. Standard immunoassay benzodiazepine screens show high cross-reactivity with nifoxipam,[13] meaning a positive panel result is expected but cannot distinguish nifoxipam from other benzodiazepines — confirmatory laboratory analysis is required for definitive identification.
Guidelines
- Test all material with reagent kits and, where possible, laboratory analysis before use. Reagent testing cannot confirm dose but can identify some substitutions.
- Start at the lowest reported active dose and do not redose for at least 4–6 hours. The 45–120 minute onset window[3] means early redosing is the most common path to unintended overdose.
- Use a milligram-precision scale. Volumetric dosing of solutions is preferable to weighing sub-milligram differences in powder.
- Keep all other depressants — especially alcohol and opioids — completely out of the session. Even low doses of nifoxipam combined with alcohol have produced rapid potentiation.[3]
- Write down what you took, how much, and when. Amnesia may prevent recall of this information, and it is critical for medical responders.
- Do not use alone. A sober sitter who knows what was taken can intervene if breathing becomes shallow or the user becomes unresponsive.
Set & Setting
Nifoxipam's extended duration (potentially spanning multiple days) demands planning that shorter-acting benzodiazepines do not. Users should clear obligations for at least 24–48 hours following administration. A trusted, sober companion is advisable given the compound's propensity for amnesia and delusions of sobriety, which may prevent self-assessment of impairment. Driving and operating machinery are unsafe for the full duration of effects, which may persist long after the user feels subjectively sober.
Aftercare & integration. The primary aftercare concern with nifoxipam is its prolonged duration. Residual sedation, cognitive impairment, and impaired coordination may persist for 24–72 hours after administration. During this period, avoid driving, important decisions, and situations requiring sharp judgment.
Hydration and light meals support recovery. Sleep disruption is common in the days following use — maintain a regular sleep schedule and avoid caffeine in the evening. If amnesia occurred during the experience, seek a trusted account of events from anyone who was present.
Recovery & Support
Benzodiazepine dependence develops with sustained use and produces a withdrawal that can be life-threatening.[5] Anyone who has used nifoxipam or other benzodiazepines regularly should not stop abruptly — medical supervision is essential for safe tapering.
Support resources include the SAMHSA National Helpline (1-800-662-4357, US), local addiction medicine services, and benzodiazepine-specific peer support communities such as BenzoBuddies. A physician experienced in benzodiazepine tapering can design a gradual dose-reduction schedule, often using a long-acting pharmaceutical benzodiazepine as a bridge.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Slow, shallow, or stopped breathing
- Blue or grey lips and fingertips
- Unresponsiveness — cannot be woken by shouting or sternal rub
- Snoring or gurgling sounds in an unconscious person (signs of airway obstruction)
Immediate steps:
- Call emergency services immediately if breathing is slow, stopped, or the person cannot be woken.
- Place the person in the recovery position (on their side, mouth facing downward) to prevent choking on vomit.
- Monitor breathing continuously until help arrives. If breathing stops, begin rescue breathing if trained.
- Do NOT induce vomiting. Do NOT leave the person alone.
What to tell the dispatcher:
- "They took a designer benzodiazepine called nifoxipam."
- State the approximate amount and time of ingestion.
- Report any other substances taken, especially opioids or alcohol.
- Describe current symptoms: breathing rate, responsiveness, skin color.
- Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil reverses benzodiazepine sedation and has been used successfully in nifoxipam cases.[14] However, nifoxipam's effects can last far longer than flumazenil's (up to 75 hours vs. 1–2 hours), so re-sedation is likely and repeated administration may be needed. Flumazenil should only be given by medical professionals.
Legal Status[edit]
Nifoxipam occupies a legal position typical of designer benzodiazepines: explicitly scheduled in a growing number of jurisdictions that have responded to its detection in drug seizures, while remaining unscheduled in many others. As a metabolite of the internationally controlled flunitrazepam (UN Convention Schedule IV), it may fall under structural analog legislation in jurisdictions where it has not been individually scheduled.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class C, Schedule 1 (Misuse of Drugs Act 1971) | Added via SI 2017/631 (May 2017); tightest control category — no recognized medical use; also covered by Psychoactive Substances Act 2016[9][2] |
| Denmark | Controlled substance | Controlled from February 18, 2016[3][2] |
| United States | Not federally scheduled | Potentially prosecutable under the Federal Analogue Act as a structural and pharmacological analog of flunitrazepam (Schedule IV); state-level scheduling may applycitation needed |
| Australia | Controlled substance (ODC listing) | Listed by the Australian Office of Drug Control; specific scheduling tier not confirmed from primary sourcescitation needed |
| Canada | Possible Schedule IV coverage | Benzodiazepine analogs may fall under CDSA Schedule IV; specific nifoxipam status requires verificationcitation needed |
| Sweden | Status unconfirmed | STRIDA project documented intoxication cases;[14] specific scheduling legislation not confirmed |
| Finland, Norway, Slovenia, France | Seizures reported 2014–2015 | Nifoxipam tablets seized in all four countries;[3] individual scheduling status not confirmed |
Analog act considerations
In the United States, the Federal Analogue Act (21 U.S.C. § 813) treats substances "substantially similar" in structure or effect to a Schedule I or II controlled substance as Schedule I when intended for human consumption. Nifoxipam is a direct metabolite of flunitrazepam (Schedule IV, not Schedule I/II), placing it in an ambiguous position under the Act's literal text. Structural similarity to other scheduled benzodiazepines may provide alternative bases for prosecution.
Nifoxipam is listed in the UNODC Early Warning Advisory substance database but is not placed under any UN convention schedule as of available data.[18]
Frequently asked questions
What is Nifoxipam?
Nifoxipam is a synthetic nitrobenzodiazepine and active metabolite of flunitrazepam that acts as a GABA-A receptor positive allosteric modulator. It emerged on novel psychoactive substance markets in 2014 and is among the lowest-potency designer benzodiazepines, with a total duration of 10–75 hours.
How long does Nifoxipam last?
Total duration by route of administration — Oral: 10 – 75 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Nifoxipam?
Psychedex publishes a dosage table for Nifoxipam on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Nifoxipam?
The highest-severity documented interactions for Nifoxipam: Opioids (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Antipsychotics (Dangerous), Atypical antipsychotics (Dangerous), Benzodiazepines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Nifoxipam addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Nifoxipam: tolerance builds rapid; full reset takes 10.5 days; cross-tolerance develops with benzodiazepines, alcohol, barbiturates, GABA-A positive allosteric modulators. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abcdSaini S, Tahlan S, Minocha N (2024) Current Therapeutic Strategies for the Management of Benzodiazepine (BZD) Withdrawal Syndrome: A Review. — Current topics in medicinal chemistry doi:10.2174/0115680266296096240408032738
- [6]
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abcdSaini S, Tahlan S, Minocha N (2024) Current Therapeutic Strategies for the Management of Benzodiazepine (BZD) Withdrawal Syndrome: A Review. — Current topics in medicinal chemistry doi:10.2174/0115680266296096240408032738
- [6]